Loading cancer entity…
Loading cancer entity…
Clinical trials
42 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00001465 | Study of the Disease Process of Lymphangioleiomyomatosis | recruiting | — | 2,000 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01484236 | National Lymphangioleiomyomatosis Registry, France(RE-LAM-CE) | recruiting | — | 200 | Vincent COTTINOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT01799538 | Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis | recruiting | Phase 1 / Phase 2 | 100 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05676099 |
Data updated 21 hours agoSource updated Sep 28, 2026source: clinicaltrials
| recruiting |
| — |
| 5,000 |
| National Tuberous Sclerosis AssociationOTHER |
| 2 |
| Jun 24, 2026 |
| clinicaltrials |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | terminated | Phase 1 | 154 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT03304678 | Discovery of Sirolimus Sensitive Biomarkers in Blood | completed | Phase 2 | 33 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06160310 | Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry) | recruiting | — | 300 | David M. RitterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05467397 | Feasibility of [11C]Acetate-PET in LAM and TSC | active not recruiting | Phase 1 / Phase 2 | 7 | Brigham and Women's HospitalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06889168 | Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)(LAMP-2) | recruiting | Phase 1 | 20 | Columbia UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07304856 | Role of Extracellular Vesicles as Biomarkers of Pulmonary Involvement in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex | recruiting | — | 80 | University of MilanOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT02432560 | Safety and Durability of Sirolimus for Treatment of LAM(MIDAS) | recruiting | — | 600 | University of CincinnatiOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT03150914 | Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial(MILED) | active not recruiting | Phase 3 | 60 | University of CincinnatiOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05727852 | Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases | enrolling by invitation | — | 400 | I.M. Sechenov First Moscow State Medical UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT01353209 | Letrozole for Lymphangioleiomyomatosis(TRAIL) | completed | Phase 2 | 17 | University of CincinnatiOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT00414648 | Efficacy and Safety of Sirolimus in LAM(MILES) | completed | Phase 3 | 89 | University of CincinnatiOTHER | 3 | Nov 2, 2023 | clinicaltrials |
| NCT05323370 | Lymphangioleiomyomatosis, a Study on Cathepsin K(LAM-CAK) | completed | — | 19 | University Hospital, ToursOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT02654340 | Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)(TuScCom) | terminated | — | 20 | CENTOGENE GmbH RostockINDUSTRY | 8 | Feb 10, 2023 | clinicaltrials |
| NCT03253913 | Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial(RESULT) | completed | Phase 2 | 25 | University of CincinnatiOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT03062943 | A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)(LAM) | completed | Phase 2 | 30 | IRCCS MultimedicaOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT02325505 | Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma | completed | — | 200 | InCor Heart InstituteOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05190627 | Effect of Loratadine in Lymphangioleiomyomatosis(LORALAM) | unknown | Phase 2 | 62 | Institut d'Investigació Biomèdica de BellvitgeOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT02484664 | COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC(COLA) | completed | Phase 2 | 12 | Brigham and Women's HospitalOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT05087134 | Characterizing LAM With 11C-Choline PET/CT | unknown | Early Phase 1 | 50 | Peking Union Medical College HospitalOTHER | 1 | Oct 21, 2021 | clinicaltrials |
| NCT04388371 | Glutamine PET Imaging in LAM | completed | Phase 1 | 5 | Vanderbilt University Medical CenterOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT00366509 | Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases | completed | — | 157 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Aug 2, 2021 | clinicaltrials |
| NCT04577937 | Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis | unknown | N/A | 15 | dr. Stefano NavaOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT01059318 | A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis | completed | Phase 2 | 24 | Novartis PharmaceuticalsINDUSTRY | 3 | Nov 19, 2020 | clinicaltrials |
| NCT02061397 | Safety of Simvastatin in LAM and TSC(SOS) | completed | Phase 1 / Phase 2 | 10 | University of PennsylvaniaOTHER | 1 | Aug 25, 2020 | clinicaltrials |
| NCT03131999 | LAM Pilot Study With Imatinib Mesylate(LAMP-1) | completed | Phase 1 / Phase 2 | 18 | Medical University of South CarolinaOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT04184193 | Benefits of Pulmonary Rehabilitation in Patients With Severe Lymphangioleiomyomatosis (LAM) | completed | — | 58 | Schön Klinik Berchtesgadener LandOTHER | 1 | Jan 21, 2020 | clinicaltrials |
| NCT00552955 | Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women | completed | — | 35 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 6, 2019 | clinicaltrials |
| NCT01687179 | Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis(SAIL) | completed | Phase 1 | 14 | Brigham and Women's HospitalOTHER | 1 | Oct 11, 2018 | clinicaltrials |
| NCT02859194 | The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients | completed | N/A | 10 | Yonsei UniversityOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00790400 | Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)(EXIST-2) | completed | Phase 3 | 118 | Novartis PharmaceuticalsINDUSTRY | 11 | Feb 17, 2017 | clinicaltrials |
| NCT00005486 | Lymphangioleiomyomatosis (LAM) Registry | completed | — | — | National Heart, Lung, and Blood Institute (NHLBI)NIH | 0 | Feb 18, 2016 | clinicaltrials |
| NCT02009241 | Pulmonary Rehabilitation in Lymphangioleiomyomatosis | completed | N/A | 40 | University of Sao Paulo General HospitalOTHER | 1 | Dec 11, 2015 | clinicaltrials |
| NCT00989742 | Doxycycline In Lymphangioleiomyomatosis (LAM) | completed | Phase 4 | 24 | University of NottinghamOTHER | 1 | Dec 2, 2015 | clinicaltrials |
| NCT00457964 | RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM | completed | Phase 1 / Phase 2 | 36 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Sep 25, 2013 | clinicaltrials |
| NCT00960895 | Pulmonary Hypertension in Lymphangioleiomyomatosis(LAM-PH) | completed | — | 20 | Groupe d'Etudes et de Recherche sur les Maladies Orphelines PulmonairesOTHER | 1 | Oct 27, 2011 | clinicaltrials |
| NCT00005906 | Treatment With Octreotide in Patients With Lymphangioleiomyomatosis | completed | Phase 2 | 4 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Apr 30, 2010 | clinicaltrials |
| NCT00490789 | Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM(TESSTAL) | unknown | Phase 2 | 14 | Cardiff UniversityOTHER | 1 | Apr 30, 2008 | clinicaltrials |
| NCT00457808 | Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM | completed | Phase 2 | 25 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Apr 9, 2007 | clinicaltrials |